Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane/Letrozole

Please see https://docs.google.com/spreadsheets/d/1GrnVsPCockqqdfxC9LWd6ndbzS2wpJVvTbCOAhn4DLM/edit?usp=sharing or Appendix A (https://drive.google.com/drive/folders/1I8FVmpPzC5wQN9DFIv1Rbwh1N0SLEv0B?usp=sharing) for full code and algorithm definitions.

Medicare timeframe: 2008 to 2018 (end of data availability)

Inclusion Criteria:

* 1\. Aged \>/= 65 years on the index date
* 2\. Enrollment in Medicare Part A, B, and D with no HMO coverage for 365 days prior to and including cohort entry date
* 3\. At least two claims with breast cancer diagnosis measured 365 days prior to drug initiation

Exclusion Criteria:

* 1\. Prior history of dementia measured anytime prior to cohort entry date
* 2\. Prior history of nursing home admission anytime prior to cohort entry date
* 3\. Prior history of Anastrozole or Exemestane/Letrozole use anytime prior to cohort entry date